Windlas Biotech

Why is Windlas Biotech Ltd falling/rising?

As of 08-Aug, Windlas Biotech Ltd's stock price is rising to 883.65, reflecting a 1.28% increase. This growth is driven by strong performance metrics, outpacing the Sensex, and increasing investor interest, alongside solid financial health.

As of 08-Aug, Windlas Biotech Ltd's stock price is rising, currently at 883.65, reflecting a change of 11.15 (1.28%) upward. This increase can be attributed to several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 3.24% compared to the Sensex's 0.52%. In the last month, the stock has also shown a positive return of 3.75%, while the Sensex has only increased by 0.41%.<BR><BR>The stock's performance year-to-date is particularly strong, with an increase of 11.14%, contrasting sharply with the Sensex's decline of 7.89%. Additionally, Windlas Biotech has demonstrated impressive long-term growth, with a remarkable 177.66% increase over the past three years, significantly outpacing the Sensex's 19.02% rise.<BR><BR>Today's performance indicates that the stock has outperformed its sector by 0.98% and has been on a consecutive gain for the last two days, with a total return of 3.53% during this period. The stock is also trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a strong upward trend.<BR><BR>Investor participation is rising, as evidenced by a 28.93% increase in delivery volume compared to the 5-day average. Furthermore, the company is net-debt free and has an attractive valuation with a return on equity (ROE) of 11.4 and a price-to-book value of 3.1, indicating that it is trading at a fair value relative to its peers. The increase in institutional investor participation, with a 0.7% rise in their stake over the previous quarter, further supports the stock's upward movement, as these investors typically have better resources for analyzing company fundamentals.<BR><BR>Overall, the combination of strong performance metrics, rising investor interest, and solid financial health contributes to the rising stock price of Windlas Biotech Ltd.

Which are the latest news on Windlas Biotech?

When is the next results date for Windlas Biotech Ltd?

The next results date for Windlas Biotech Ltd is 10 August 2026.

The next results date for Windlas Biotech Ltd is scheduled for 10 August 2026.

Should I buy, sell or hold Windlas Biotech Ltd?

What does Windlas Biotech do?

No Company Information Available

How big is Windlas Biotech?

As of 10th June, Windlas Biotech Ltd has a market capitalization of 1,708.00 Cr, with net sales of 904.09 Cr and a net profit of 66.45 Cr in the latest four quarters. The company reported shareholder's funds of 505.77 Cr and total assets of 760.17 Cr for the annual period ending in March 2025.

As of 10th June, Windlas Biotech Ltd has a market capitalization of 1,708.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Windlas Biotech reported net sales of 904.09 Cr and a net profit of 66.45 Cr.<BR><BR>For the latest annual period ending in March 2025, the company had shareholder's funds amounting to 505.77 Cr and total assets of 760.17 Cr.

Who are the peers of the Windlas Biotech?

Windlas Biotech's peers include Venus Remedies, Hikal, Indoco Remedies, and others. Key metrics show excellent management risk for Windlas Biotech, but below-average growth, with a 1-year return of -12.26%, compared to Venus Remedies' 269.10% and Hikal's -52.29%.

Peers: The peers of Windlas Biotech are Venus Remedies, Hikal, Indoco Remedies, NGL Fine Chem, Hester Bios, Amrutanjan Healt, Ind-Swift Labs., Syncom Formul., Sakar Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at NGL Fine Chem, Windlas Biotech, Amrutanjan Healt, and the rest. Average management risk is found at Venus Remedies, Hikal, Indoco Remedies, Hester Bios, Syncom Formul., Sakar Healthcare, and the rest. Below Average management risk is noted at Ind-Swift Labs. Growth is rated as Good for Venus Remedies, while Below Average growth is seen at Hikal, Indoco Remedies, Hester Bios, Windlas Biotech, Amrutanjan Healt, Syncom Formul., and the rest. Excellent capital structure is noted for NGL Fine Chem, Windlas Biotech, Amrutanjan Healt, and Syncom Formul., while Average capital structure is found at Sakar Healthcare, and Below Average at Hikal, Indoco Remedies, Hester Bios, and Ind-Swift Labs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Venus Remedies at 269.10%, while the lowest is Hikal at -52.29%. Windlas Biotech's 1-year return is -12.26%, which is higher than Hikal's but lower than Venus Remedies. Additionally, Hikal, Indoco Remedies, Hester Bios, Amrutanjan Healt, and Syncom Formul. have negative six-month returns.

Are Windlas Biotech Ltd latest results good or bad?

Windlas Biotech Ltd's latest results show strong revenue growth of 17.66% year-on-year, reaching ₹238.50 crores, but profitability has declined, with net profit down 1.78% and operating margins decreasing, raising concerns about operational efficiency and cost management. Investors should approach the stock with caution due to these profitability challenges.

Windlas Biotech Ltd's latest results present a mixed picture. On one hand, the company achieved a notable revenue growth of 17.66% year-on-year, reaching ₹238.50 crores in Q4 FY26, which is the highest quarterly revenue in its recent history. This indicates strong top-line momentum and the ability to secure contracts in the competitive contract development and manufacturing organization (CDMO) space.<BR><BR>However, the profitability metrics tell a different story. The net profit for the quarter was ₹15.99 crores, reflecting a year-on-year decline of 1.78%. This decline, despite a quarter-on-quarter improvement of 6.60%, raises concerns about the company's operational efficiency. Additionally, the operating margin decreased to 10.60%, down 201 basis points from the previous year, and the profit after tax (PAT) margin fell to 6.70%, down 133 basis points year-on-year. <BR><BR>The significant increase in employee costs, which rose by 29.56% year-on-year, has outpaced revenue growth and is a primary factor behind the margin compression. This suggests that while Windlas Biotech is growing its sales, it is struggling to translate that growth into profitability, which is a critical concern for investors.<BR><BR>Overall, while the revenue growth is a positive sign, the deterioration in profitability and margins indicates operational challenges that need to be addressed. Investors may want to approach the stock with caution, given the current trends in profitability and the company's ability to manage costs effectively.

Is Windlas Biotech overvalued or undervalued?

As of December 4, 2025, Windlas Biotech is considered undervalued with an attractive valuation grade, supported by a PE ratio of 24.65 and favorable financial metrics compared to peers, despite a year-to-date stock performance lagging behind the Sensex.

As of 4 December 2025, Windlas Biotech's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, supported by a PE ratio of 24.65, an EV to EBITDA of 13.58, and a ROCE of 24.60%. In comparison to its peers, Windlas Biotech's valuation appears favorable, especially when contrasted with Sun Pharma, which has a significantly higher PE ratio of 37.78, and Divi's Lab, which stands at 68.56.<BR><BR>Despite recent stock performance lagging behind the Sensex, with a year-to-date return of -23.81% compared to the Sensex's 9.12%, the underlying financial metrics suggest that Windlas Biotech presents a compelling investment opportunity. The company's PEG ratio of 2.73 also indicates potential for growth relative to its earnings, further reinforcing the assessment of it being undervalued in the current market landscape.

Is Windlas Biotech technically bullish or bearish?

As of November 12, 2025, Windlas Biotech's technical trend has shifted to bearish, indicated by negative signals from MACD, RSI, Bollinger Bands, moving averages, KST, and OBV, along with significant underperformance compared to the Sensex.

As of 12 November 2025, the technical trend for Windlas Biotech has changed from mildly bearish to bearish. The current stance is bearish with a strong indication of weakness. Key indicators driving this assessment include a bearish MACD on the weekly chart, a bearish RSI on the monthly chart, and bearish signals from Bollinger Bands and moving averages across daily and weekly time frames. Additionally, the KST and OBV indicators are also bearish on the weekly chart, reinforcing the overall bearish sentiment. The stock has underperformed significantly compared to the Sensex over various periods, further supporting the bearish outlook.

How has been the historical performance of Windlas Biotech?

Windlas Biotech has shown consistent growth from March 2020 to March 2025, with net sales increasing from 328.85 Cr to 759.88 Cr and profit after tax rising from 16.21 Cr to 60.99 Cr, reflecting strong profitability and asset expansion. Total assets grew from 337.82 Cr to 760.17 Cr, indicating robust financial performance.

Answer:<BR>The historical performance of Windlas Biotech shows a consistent growth trajectory in net sales and profits over the years, culminating in the latest figures for March 2025.<BR><BR>Breakdown:<BR>Windlas Biotech has demonstrated significant growth in net sales, increasing from 328.85 Cr in March 2020 to 759.88 Cr in March 2025. This upward trend is mirrored in total operating income, which also rose from 328.85 Cr to 759.88 Cr during the same period. The company's operating profit (PBDIT) has similarly improved, reaching 112.13 Cr in March 2025, up from 43.95 Cr in March 2020. Profit before tax has shown a steady increase, climbing from 32.14 Cr in March 2020 to 79.76 Cr in March 2025, while profit after tax reached 60.99 Cr in March 2025, compared to 16.21 Cr in March 2020. The company's total assets have expanded from 337.82 Cr in March 2020 to 760.17 Cr in March 2025, reflecting a robust growth in both current and non-current assets. Total liabilities have also increased, from 296.12 Cr in March 2020 to 760.17 Cr in March 2025, primarily driven by an increase in current liabilities. Cash flow from operating activities has fluctuated, with a notable cash flow of 68.00 Cr in March 2025, although the net cash outflow was recorded at -4.00 Cr for the same period. Overall, Windlas Biotech's financial performance indicates a strong growth trajectory with improving profitability and asset base over the years.

Has Windlas Biotech declared dividend?

Windlas Biotech Ltd has declared an 80% dividend, amounting to ₹4 per share, with an ex-date of September 5, 2023. Despite this, the dividend yield is 0%, and total returns have varied significantly over different periods, showing strong performance over 2 and 3 years.

Windlas Biotech Ltd has declared an 80% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 80%<BR>- Amount per share: 4<BR>- Ex-date: 05 Sep 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, Windlas Biotech experienced a price return of -19.79%, with no dividend return, resulting in a total return of -19.79%.<BR><BR>Over the past year, the price return was 37.84%, and there was no dividend return, leading to a total return of 37.84%.<BR><BR>In the 2-year period, the price return was 229.02%, with a dividend return of 1.30%, culminating in a total return of 230.32%.<BR><BR>For the 3-year period, the price return stood at 300.9%, with a dividend return of 3.51%, resulting in a total return of 304.41%.<BR><BR>In the 4-year period, there was no price return and no dividend return, resulting in a total return of 0.0%.<BR><BR>Over the last 5 years, there was also no price return and no dividend return, leading to a total return of 0.0%.<BR><BR>Overall, Windlas Biotech has declared a significant dividend, but the dividend yield remains at 0%. The total returns show a strong performance over longer periods, particularly in the 2 and 3-year spans, despite recent fluctuations in the shorter term.